{"version":"1.0","type":"rich","provider_name":"NULLPEN","provider_url":"https://nullpen.com","title":"Trial results posted: A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China","cache_age":300,"width":400,"height":320,"html":"<iframe src=\"https://nullpen.com/embed?story=sha256%3A907a5e5b6adfc68c8fb6e0b6b4fe966b5c00a4e00cbcdb940776a578b65bde8a\" title=\"Trial results posted: A Sub-study Trial of Epcoritamab vs Investigator&apos;s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China\" width=\"400\" height=\"320\" loading=\"lazy\" style=\"border:0;max-width:100%\" referrerpolicy=\"strict-origin-when-cross-origin\" sandbox=\"allow-popups allow-popups-to-escape-sandbox\"></iframe>"}